| 1 |
Mandal D, Lohan S, Sajid MI, Alhazza A, Tiwari RK, Parang K, Montazeri Aliabadi H. Modified Linear Peptides Effectively Silence STAT-3 in Breast Cancer and Ovarian Cancer Cell Lines. Pharmaceutics 2023;15. [PMID: 36839988 DOI: 10.3390/pharmaceutics15020666] [Reference Citation Analysis]
|
| 2 |
Adhikary S, Jahnavi T, Keerthana Mol J, Asha Ananthi A, Gokulakannan M, Pathak S. Mouse as a Preclinical Model for Studying Small Noncoding RNAs Involved in Colorectal Cancer. Handbook of Animal Models and its Uses in Cancer Research 2023. [DOI: 10.1007/978-981-19-3824-5_48] [Reference Citation Analysis]
|
| 3 |
Lu YF, Zhou JP, Zhou QM, Yang XY, Wang XJ, Yu JN, Zhang JG, Du YZ, Yu RS. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma. J Nanobiotechnology 2022;20:351. [PMID: 35907841 DOI: 10.1186/s12951-022-01565-9] [Reference Citation Analysis]
|
| 4 |
Karmakar AK, Hasan MS, Sreemani A, Das Jayanta A, Hasan MM, Tithe NA, Biswas P. A review on the current progress of layered double hydroxide application in biomedical sectors. Eur Phys J Plus 2022;137. [DOI: 10.1140/epjp/s13360-022-02993-0] [Reference Citation Analysis]
|
| 5 |
Khalil IA, Harashima H. Gene Therapy: Introduction and Current Status. The ADME Encyclopedia 2022. [DOI: 10.1007/978-3-030-84860-6_114] [Reference Citation Analysis]
|
| 6 |
Adhikary S, Jahnavi T, Keerthana Mol J, Asha Ananthi A, Gokulakannan M, Pathak S. Mouse as a Preclinical Model for Studying Small Noncoding RNAs Involved in Colorectal Cancer. Handbook of Animal Models and its Uses in Cancer Research 2022. [DOI: 10.1007/978-981-19-1282-5_48-1] [Reference Citation Analysis]
|
| 7 |
Mirzaei S, Gholami MH, Hashemi F, Zabolian A, Hushmandi K, Rahmanian V, Entezari M, Girish YR, Sharath Kumar KS, Aref AR, Makvandi P, Ashrafizadeh M, Zarrabi A, Khan H. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy. Life Sci 2021;277:119430. [PMID: 33789144 DOI: 10.1016/j.lfs.2021.119430] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 18.5] [Reference Citation Analysis]
|
| 8 |
Savarin M, Kamensek U, Znidar K, Todorovic V, Sersa G, Cemazar M. Evaluation of a Novel Plasmid for Simultaneous Gene Electrotransfer-Mediated Silencing of CD105 and CD146 in Combination with Irradiation. Int J Mol Sci 2021;22:3069. [PMID: 33802812 DOI: 10.3390/ijms22063069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 9 |
Lim MSH, Ohtsuki T, Takenaka F, Kobayashi K, Akehi M, Uji H, Kobuchi H, Sasaki T, Ozeki E, Matsuura E. A Novel 89Zr-labeled DDS Device Utilizing Human IgG Variant (scFv): "Lactosome" Nanoparticle-Based Theranostics for PET Imaging and Targeted Therapy. Life (Basel) 2021;11:158. [PMID: 33670777 DOI: 10.3390/life11020158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 10 |
Lim MSH, Nishiyama Y, Ohtsuki T, Watanabe K, Kobuchi H, Kobayashi K, Matsuura E. Lactosome-Conjugated siRNA Nanoparticles for Photo-Enhanced Gene Silencing in Cancer Cells. J Pharm Sci 2021;110:1788-98. [PMID: 33529684 DOI: 10.1016/j.xphs.2021.01.026] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Khalil IA, Harashima H. Gene Therapy: Introduction and Current Status. The ADME Encyclopedia 2021. [DOI: 10.1007/978-3-030-51519-5_114-1] [Reference Citation Analysis]
|
| 12 |
Li Y, Zhao Z, Lin CY, Liu Y, Staveley-OCarroll KF, Li G, Cheng K. Silencing PCBP2 normalizes desmoplastic stroma and improves the antitumor activity of chemotherapy in pancreatic cancer. Theranostics 2021;11:2182-200. [PMID: 33500719 DOI: 10.7150/thno.53102] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 13 |
Padayachee J, Daniels A, Balgobind A, Ariatti M, Singh M. HER-2/neu and MYC gene silencing in breast cancer: therapeutic potential and advancement in nonviral nanocarrier systems. Nanomedicine (Lond) 2020;15:1437-52. [PMID: 32515263 DOI: 10.2217/nnm-2019-0459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 14 |
Hussein Kamareddine M, Ghosn Y, Tawk A, Elia C, Alam W, Makdessi J, Farhat S. Organic Nanoparticles as Drug Delivery Systems and Their Potential Role in the Treatment of Chronic Myeloid Leukemia. Technol Cancer Res Treat 2019;18:1533033819879902. [PMID: 31865865 DOI: 10.1177/1533033819879902] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 15 |
Chen W, Feng P, Liu K, Wu M, Lin H. Computational Identification of Small Interfering RNA Targets in SARS-CoV-2. Virol Sin 2020;35:359-61. [PMID: 32297156 DOI: 10.1007/s12250-020-00221-6] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 12.7] [Reference Citation Analysis]
|
| 16 |
Paramasivan P, Kankia IH, Langdon SP, Deeni YY. Emerging role of nuclear factor erythroid 2-related factor 2 in the mechanism of action and resistance to anticancer therapies. Cancer Drug Resist 2019;2:490-515. [PMID: 35582567 DOI: 10.20517/cdr.2019.57] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 17 |
Aghamiri S, Jafarpour A, Malekshahi ZV, Mahmoudi Gomari M, Negahdari B. Targeting siRNA in colorectal cancer therapy: Nanotechnology comes into view. J Cell Physiol 2019;234:14818-27. [PMID: 30919964 DOI: 10.1002/jcp.28281] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
| 18 |
Choi DH, Lee J, Nam J, Kim Y, Park YJ, Park YS. Covalent conjugates of granulin-epithelial precursor-siRNA with arginine-rich peptide for improved stability and intracellular delivery in hepatoma cells. Mol Cell Toxicol 2019;15:245-54. [DOI: 10.1007/s13273-019-0028-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 19 |
Wu H, Chaudhary AK, Mahato RI. Gene Therapy. Pharmaceutical Biotechnology 2019. [DOI: 10.1007/978-3-030-00710-2_16] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Peng Y, Diaz-dussan D, Kumar P, Narain R. Acid Degradable Cationic Galactose-Based Hyperbranched Polymers as Nanotherapeutic Vehicles for Epidermal Growth Factor Receptor (EGFR) Knockdown in Cervical Carcinoma. Biomacromolecules 2018;19:4052-8. [DOI: 10.1021/acs.biomac.8b01066] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 21 |
Suffian IFM, Wang JT, Faruqu FN, Benitez J, Nishimura Y, Ogino C, Kondo A, Al-Jamal KT. Engineering Human Epidermal Growth Receptor 2-Targeting Hepatitis B Virus Core Nanoparticles for siRNA Delivery in Vitro and in Vivo. ACS Appl Nano Mater 2018;1:3269-82. [PMID: 30613831 DOI: 10.1021/acsanm.8b00480] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
|
| 22 |
Chen L, Yuan D, Zhao R, Li H, Zhu J. Suppression of TSPAN1 by RNA Interference Inhibits Proliferation and Invasion of Colon Cancer Cells in Vitro. Tumori 2010;96:744-50. [DOI: 10.1177/030089161009600517] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 23 |
Jamali A, Mottaghitalab F, Abdoli A, Dinarvand M, Esmailie A, Kheiri MT, Atyabi F. Inhibiting influenza virus replication and inducing protection against lethal influenza virus challenge through chitosan nanoparticles loaded by siRNA. Drug Deliv and Transl Res 2018;8:12-20. [DOI: 10.1007/s13346-017-0426-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
|
| 24 |
Rhana P, Trivelato RR Junior, Beirão PSL, Cruz JS, Rodrigues ALP. Is there a role for voltage-gated Na+ channels in the aggressiveness of breast cancer? Braz J Med Biol Res 2017;50:e6011. [PMID: 28591378 DOI: 10.1590/1414-431X20176011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 25 |
Wang H, Zhang X, Zheng X, Lan Z, Shi J, Jiang J, Zwiep T, Li Q, Quan D, Zhang ZX, Min W. Prevention of allograft rejection in heart transplantation through concurrent gene silencing of TLR and Kinase signaling pathways. Sci Rep 2016;6:33869. [PMID: 27659428 DOI: 10.1038/srep33869] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 26 |
Srikar R, Suresh D, Zambre A, Taylor K, Chapman S, Leevy M, Upendran A, Kannan R. Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown. Sci Rep 2016;6:30245. [PMID: 27530552 DOI: 10.1038/srep30245] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 27 |
Wysocka O, Kulbacka J, Saczko J. Adjuvant, neoadjuvant, and experimental regimens in overcoming pancreatic ductal adenocarcinoma. Prz Gastroenterol 2016;11:155-62. [PMID: 27713776 DOI: 10.5114/pg.2016.61438] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 28 |
Quan S, Kumar P, Narain R. Cationic Galactose-Conjugated Copolymers for Epidermal Growth Factor (EGFR) Knockdown in Cervical Adenocarcinoma. ACS Biomater Sci Eng 2016;2:853-9. [DOI: 10.1021/acsbiomaterials.6b00085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
|
| 29 |
Wu Z, Song N, Menz R, Pingali B, Yang YW, Zheng Y. Nanoparticles functionalized with supramolecular host-guest systems for nanomedicine and healthcare. Nanomedicine (Lond) 2015;10:1493-514. [PMID: 25996121 DOI: 10.2217/nnm.15.1] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 30 |
Talaiezadeh A, Jalali F, Galehdari H, Khodadadi A. Time depended Bcl-2 inhibition might be useful for a targeted drug therapy. Cancer Cell Int 2015;15:105. [PMID: 26535028 DOI: 10.1186/s12935-015-0254-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 31 |
Schumann C, Taratula O, Khalimonchuk O, Palmer AL, Cronk LM, Jones CV, Escalante CA, Taratula O. ROS-induced nanotherapeutic approach for ovarian cancer treatment based on the combinatorial effect of photodynamic therapy and DJ-1 gene suppression. Nanomedicine: Nanotechnology, Biology and Medicine 2015;11:1961-70. [DOI: 10.1016/j.nano.2015.07.005] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 32 |
Zhang X, Liu D, Hayashida Y, Okazoe H, Hashimoto T, Ueda N, Sugimoto M, Kakehi Y. G Protein-Coupled Receptor 87 (GPR87) Promotes Cell Proliferation in Human Bladder Cancer Cells. Int J Mol Sci 2015;16:24319-31. [PMID: 26473854 DOI: 10.3390/ijms161024319] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 33 |
Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells. Eur J Cancer 2015;51:2480-9. [PMID: 26254808 DOI: 10.1016/j.ejca.2015.05.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 34 |
Child HW, Hernandez Y, Conde J, Mullin M, Baptista P, de la Fuente JM, Berry CC. Gold nanoparticle-siRNA mediated oncogene knockdown at RNA and protein level, with associated gene effects. Nanomedicine 2015;10:2513-25. [DOI: 10.2217/nnm.15.95] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 35 |
Mukherjee A, Bhattacharyya J, Sagar MV, Chaudhuri A. Liposomally encapsulated CDC20 siRNA inhibits both solid melanoma tumor growth and spontaneous growth of intravenously injected melanoma cells on mouse lung. Drug Deliv Transl Res 2013;3:224-34. [PMID: 25788131 DOI: 10.1007/s13346-013-0141-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 36 |
Stimac M, Dolinsek T, Lampreht U, Cemazar M, Sersa G. Gene Electrotransfer of Plasmid with Tissue Specific Promoter Encoding shRNA against Endoglin Exerts Antitumor Efficacy against Murine TS/A Tumors by Vascular Targeted Effects. PLoS One 2015;10:e0124913. [PMID: 25909447 DOI: 10.1371/journal.pone.0124913] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 37 |
Staedtler AM, Hellmund M, Sheikhi Mehrabadi F, Thota BNS, Zollner TM, Koch M, Haag R, Schmidt N. Optimized effective charge density and size of polyglycerol amines leads to strong knockdown efficacy in vivo. J Mater Chem B 2015;3:8993-9000. [DOI: 10.1039/c5tb01466b] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 38 |
Muralidharan R, Babu A, Basalingappa K, Mehta M, Munshi A, Ramesh R. Designing of Tumor-Targeted HuR siRNA Nanoparticle as a Therapeutic for Lung Cancer. Multi-Targeted Approach to Treatment of Cancer 2015. [DOI: 10.1007/978-3-319-12253-3_17] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 39 |
Yang C, Hu R, Anderson T, Wang Y, Lin G, Law W, Lin W, Nguyen QT, Toh HT, Yoon HS, Chen C, Yong K. Biodegradable nanoparticle-mediated K-ras down regulation for pancreatic cancer gene therapy. J Mater Chem B 2015;3:2163-72. [DOI: 10.1039/c4tb01623h] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 40 |
Prosen L, Markelc B, Dolinsek T, Music B, Cemazar M, Sersa G. Mcam Silencing With RNA Interference Using Magnetofection has Antitumor Effect in Murine Melanoma. Mol Ther Nucleic Acids 2014;3:e205. [PMID: 25350580 DOI: 10.1038/mtna.2014.56] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 41 |
Gandhi NS, Tekade RK, Chougule MB. Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release 2014;194:238-56. [PMID: 25204288 DOI: 10.1016/j.jconrel.2014.09.001] [Cited by in Crossref: 238] [Cited by in F6Publishing: 259] [Article Influence: 26.4] [Reference Citation Analysis]
|
| 42 |
Liu C, Huang Z, Jiang H, Shi F. The sirtuin 3 expression profile is associated with pathological and clinical outcomes in colon cancer patients. Biomed Res Int 2014;2014:871263. [PMID: 25105144 DOI: 10.1155/2014/871263] [Cited by in Crossref: 13] [Cited by in F6Publishing: 32] [Article Influence: 1.4] [Reference Citation Analysis]
|
| 43 |
Ziogas DE. Genome-based approaches for the diagnosis of breast cancer: a review with perspective. Breast Cancer Management 2014;3:173-193. [DOI: 10.2217/bmt.13.81] [Reference Citation Analysis]
|
| 44 |
Tan YF, Mundargi RC, Chen MH, Lessig J, Neu B, Venkatraman SS, Wong TT. Layer-by-layer nanoparticles as an efficient siRNA delivery vehicle for SPARC silencing. Small 2014;10:1790-8. [PMID: 24510544 DOI: 10.1002/smll.201303201] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 5.1] [Reference Citation Analysis]
|
| 45 |
Khan IU, Serra CA, Anton N, Vandamme T. Microfluidics: A focus on improved cancer targeted drug delivery systems. Journal of Controlled Release 2013;172:1065-74. [DOI: 10.1016/j.jconrel.2013.07.028] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 46 |
Bagheri F, Safarian S, Eslaminejad MB, Sheibani N. siRNA-mediated knock-down of DFF45 amplifies doxorubicin therapeutic effects in breast cancer cells. Cell Oncol (Dordr) 2013;36:515-26. [PMID: 24277473 DOI: 10.1007/s13402-013-0157-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 47 |
Qin B, Chen Z, Jin W, Cheng K. Development of cholesteryl peptide micelles for siRNA delivery. J Control Release 2013;172:159-68. [PMID: 23968830 DOI: 10.1016/j.jconrel.2013.07.033] [Cited by in Crossref: 25] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 48 |
Wu H, Mahato RI. Gene Therapy. Pharmaceutical Biotechnology 2013. [DOI: 10.1007/978-1-4614-6486-0_24] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 49 |
Muroski ME, Kogot JM, Strouse GF. Bimodal gold nanoparticle therapeutics for manipulating exogenous and endogenous protein levels in mammalian cells. J Am Chem Soc 2012;134:19722-30. [PMID: 23131062 DOI: 10.1021/ja307502x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 50 |
Cui L, Cohen JL, Chu CK, Wich PR, Kierstead PH, Fréchet JMJ. Conjugation Chemistry through Acetals toward a Dextran-Based Delivery System for Controlled Release of siRNA. J Am Chem Soc 2012;134:15840-8. [DOI: 10.1021/ja305552u] [Cited by in Crossref: 71] [Cited by in F6Publishing: 73] [Article Influence: 6.5] [Reference Citation Analysis]
|
| 51 |
Hu Q, Li W, Hu X, Hu Q, Shen J, Jin X, Zhou J, Tang G, Chu PK. Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly. Biomaterials 2012;33:6580-91. [DOI: 10.1016/j.biomaterials.2012.05.060] [Cited by in Crossref: 99] [Cited by in F6Publishing: 104] [Article Influence: 9.0] [Reference Citation Analysis]
|
| 52 |
Li JM, Wang YY, Zhao MX, Tan CP, Li YQ, Le XY, Ji LN, Mao ZW. Multifunctional QD-based co-delivery of siRNA and doxorubicin to HeLa cells for reversal of multidrug resistance and real-time tracking. Biomaterials 2012;33:2780-90. [PMID: 22243797 DOI: 10.1016/j.biomaterials.2011.12.035] [Cited by in Crossref: 146] [Cited by in F6Publishing: 137] [Article Influence: 13.3] [Reference Citation Analysis]
|
| 53 |
Mendonça L, Pedroso de Lima M, Simões S. Targeted lipid-based systems for siRNA delivery. Journal of Drug Delivery Science and Technology 2012;22:65-73. [DOI: 10.1016/s1773-2247(12)50006-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 54 |
Benfer M, Kissel T. Cellular uptake mechanism and knockdown activity of siRNA-loaded biodegradable DEAPA-PVA-g-PLGA nanoparticles. Eur J Pharm Biopharm 2012;80:247-56. [PMID: 22085653 DOI: 10.1016/j.ejpb.2011.10.021] [Cited by in Crossref: 63] [Cited by in F6Publishing: 69] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 55 |
Liu J, Jiang Z, Zhang S, Liu C, Gross RA, Kyriakides TR, Saltzman WM. Biodegradation, biocompatibility, and drug delivery in poly(ω-pentadecalactone-co-p-dioxanone) copolyesters. Biomaterials 2011;32:6646-54. [PMID: 21641030 DOI: 10.1016/j.biomaterials.2011.05.046] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 56 |
Mukerjee A, Shankardas J, Ranjan AP, Vishwanatha JK. Efficient nanoparticle mediated sustained RNA interference in human primary endothelial cells. Nanotechnology 2011;22:445101. [PMID: 21990205 DOI: 10.1088/0957-4484/22/44/445101] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 57 |
Boudreau RL, Spengler RM, Davidson BL. Rational design of therapeutic siRNAs: minimizing off-targeting potential to improve the safety of RNAi therapy for Huntington's disease. Mol Ther 2011;19:2169-77. [PMID: 21952166 DOI: 10.1038/mt.2011.185] [Cited by in Crossref: 59] [Cited by in F6Publishing: 62] [Article Influence: 4.9] [Reference Citation Analysis]
|
| 58 |
Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S, Pantazis P, Anant S, Ramanujam RP, Houchen CW. Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism. J Nanobiotechnology. 2011;9:40. [PMID: 21929751 DOI: 10.1186/1477-3155-9-40] [Cited by in Crossref: 115] [Cited by in F6Publishing: 126] [Article Influence: 9.6] [Reference Citation Analysis]
|
| 59 |
Villares GJ, Zigler M, Bar-Eli M. The emerging role of the thrombin receptor (PAR-1) in melanoma metastasis--a possible therapeutic target. Oncotarget 2011;2:8-17. [PMID: 21378407 DOI: 10.18632/oncotarget.211] [Cited by in Crossref: 36] [Cited by in F6Publishing: 39] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 60 |
Ghigna C, Valacca C, Biamonti G. Alternative splicing and tumor progression. Curr Genomics. 2008;9:556-570. [PMID: 19516963 DOI: 10.2174/138920208786847971] [Cited by in Crossref: 126] [Cited by in F6Publishing: 135] [Article Influence: 10.5] [Reference Citation Analysis]
|
| 61 |
Kumari A, Kumar V, Yadav SK. Nanocarriers: a tool to overcome biological barriers in siRNA delivery. Expert Opinion on Biological Therapy 2011;11:1327-39. [DOI: 10.1517/14712598.2011.587801] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 62 |
Liu D, Kadota K, Ueno M, Nakashima N, Yokomise H, Huang CL. Adenoviral vector expressing short hairpin RNA targeting Wnt2B has an effective antitumour activity against Wnt2B2-overexpressing tumours. Eur J Cancer 2012;48:1208-18. [PMID: 21646015 DOI: 10.1016/j.ejca.2011.05.003] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
|
| 63 |
Tagami T, Suzuki T, Hirose K, Barichello JM, Yamazaki N, Asai T, Oku N, Ishida T, Kiwada H. Argonaute2 is a potential target for siRNA-based cancer therapy for HT1080 human fibrosarcoma. Drug Deliv and Transl Res 2011;1:277-88. [DOI: 10.1007/s13346-011-0025-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 64 |
Efthymiou TC, Desaulniers J. Synthesis and properties of oligonucleotides that contain a triazole-linked nucleic acid dimer. J Heterocyclic Chem 2011;48:533-9. [DOI: 10.1002/jhet.532] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 65 |
Bergé M, Bonnin P, Sulpice E, Vilar J, Allanic D, Silvestre JS, Lévy BI, Tucker GC, Tobelem G, Merkulova-Rainon T. Small interfering RNAs induce target-independent inhibition of tumor growth and vasculature remodeling in a mouse model of hepatocellular carcinoma. Am J Pathol. 2010;177:3192-3201. [PMID: 20971743 DOI: 10.2353/ajpath.2010.100157] [Cited by in Crossref: 40] [Cited by in F6Publishing: 45] [Article Influence: 3.1] [Reference Citation Analysis]
|
| 66 |
Kanai R, Wakimoto H, Cheema T, Rabkin SD. Oncolytic herpes simplex virus vectors and chemotherapy: are combinatorial strategies more effective for cancer? Future Oncol 2010;6:619-34. [PMID: 20373873 DOI: 10.2217/fon.10.18] [Cited by in Crossref: 44] [Cited by in F6Publishing: 46] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 67 |
Yu CH, Noteborn MH, Olsthoorn RC. Stimulation of ribosomal frameshifting by antisense LNA. Nucleic Acids Res 2010;38:8277-83. [PMID: 20693527 DOI: 10.1093/nar/gkq650] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 68 |
Jiang GM, He YW, Fang R, Zhang G, Zeng J, Yi YM, Zhang S, Bu XZ, Cai SH, Du J. Sodium butyrate down-regulation of indoleamine 2, 3-dioxygenase at the transcriptional and post-transcriptional levels. Int J Biochem Cell Biol 2010;42:1840-6. [PMID: 20691806 DOI: 10.1016/j.biocel.2010.07.020] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 69 |
Buhrman JS, Cheema TA, Fulci G. Engineering Herpes Simplex Virus for Cancer Oncolytic Virotherapy. Emerging Cancer Therapy 2010. [DOI: 10.1002/9780470626528.ch7] [Reference Citation Analysis]
|
| 70 |
Mendonça LS, Moreira JN, de Lima MCP, Simões S. Co-encapsulation of anti-BCR-ABL siRNA and imatinib mesylate in transferrin receptor-targeted sterically stabilized liposomes for chronic myeloid leukemia treatment. Biotechnol Bioeng 2010;107:884-93. [DOI: 10.1002/bit.22858] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 2.7] [Reference Citation Analysis]
|
| 71 |
Mendonça LS, Firmino F, Moreira JN, Pedroso de Lima MC, Simões S. Transferrin receptor-targeted liposomes encapsulating anti-BCR-ABL siRNA or asODN for chronic myeloid leukemia treatment. Bioconjug Chem 2010;21:157-68. [PMID: 20000596 DOI: 10.1021/bc9004365] [Cited by in Crossref: 75] [Cited by in F6Publishing: 77] [Article Influence: 5.8] [Reference Citation Analysis]
|
| 72 |
Wang YH, Xiong J, Wang SF, Yu Y, Wang B, Chen YX, Shi HF, Qiu Y. Lentivirus-mediated shRNA targeting insulin-like growth factor-1 receptor (IGF-1R) enhances chemosensitivity of osteosarcoma cells in vitro and in vivo. Mol Cell Biochem 2010;341:225-33. [PMID: 20376536 DOI: 10.1007/s11010-010-0453-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 73 |
Chang Y, Jiang HJ, Sun XM, Cai XK, He XX, Li PY, Tang WX, Song YH, Lin JS. Hepatic stellate cell-specific gene silencing induced by an artificial microRNA for antifibrosis in vitro. Dig Dis Sci 2010;55:642-53. [PMID: 19890714 DOI: 10.1007/s10620-009-1021-z] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 74 |
Giaginis C, Zarros A, Alexandrou P, Klijanienko J, Delladetsima I, Theocharis S. Evaluation of coxsackievirus and adenovirus receptor expression in human benign and malignant thyroid lesions. APMIS 2010;118:210-21. [DOI: 10.1111/j.1600-0463.2009.02582.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 75 |
Horie K, Tsuchihara M, Nakatsura T. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G1 arrest induction. Cancer Science 2010;101:913-9. [DOI: 10.1111/j.1349-7006.2009.01476.x] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 76 |
Sanderson MP, Gelling SJ, Rippmann JF, Schnapp A. Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells. Cell Immunol 2010;262:28-34. [PMID: 20053395 DOI: 10.1016/j.cellimm.2009.12.004] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
|
| 77 |
Onkal R, Djamgoz MB. Molecular pharmacology of voltage-gated sodium channel expression in metastatic disease: Clinical potential of neonatal Nav1.5 in breast cancer. European Journal of Pharmacology 2009;625:206-19. [DOI: 10.1016/j.ejphar.2009.08.040] [Cited by in Crossref: 88] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
|
| 78 |
Ladewig K, Niebert M, Xu ZP, Gray PP, Lu GQ. Efficient siRNA delivery to mammalian cells using layered double hydroxide nanoparticles. Biomaterials 2010;31:1821-9. [PMID: 19922997 DOI: 10.1016/j.biomaterials.2009.10.058] [Cited by in Crossref: 154] [Cited by in F6Publishing: 156] [Article Influence: 11.0] [Reference Citation Analysis]
|
| 79 |
Yu X, Zhang Y, Chen C, Yao Q, Li M. Targeted drug delivery in pancreatic cancer. Biochim Biophys Acta. 2010;1805:97-104. [PMID: 19853645 DOI: 10.1016/j.bbcan.2009.10.001] [Cited by in Crossref: 16] [Cited by in F6Publishing: 35] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 80 |
Cun D, Foged C, Yang M, Frøkjaer S, Nielsen HM. Preparation and characterization of poly(DL-lactide-co-glycolide) nanoparticles for siRNA delivery. Int J Pharm 2010;390:70-5. [PMID: 19836438 DOI: 10.1016/j.ijpharm.2009.10.023] [Cited by in Crossref: 79] [Cited by in F6Publishing: 84] [Article Influence: 5.6] [Reference Citation Analysis]
|
| 81 |
Ji AM, Su D, Che O, Li WS, Sun L, Zhang ZY, Yang B, Xu F. Functional gene silencing mediated by chitosan/siRNA nanocomplexes. Nanotechnology 2009;20:405103. [DOI: 10.1088/0957-4484/20/40/405103] [Cited by in Crossref: 50] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
|
| 82 |
Furalyov VA, Kravchenko IV, Popov VO. Small interfering RNA targeting the human myostatin gene. Mol Biol 2009;43:586-90. [DOI: 10.1134/s0026893309040098] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 83 |
Sato T, Gotoh N. The FRS2 family of docking/scaffolding adaptor proteins as therapeutic targets of cancer treatment. Expert Opin Ther Targets 2009;13:689-700. [PMID: 19456272 DOI: 10.1517/14728220902942330] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 84 |
Tseng YC, Mozumdar S, Huang L. Lipid-based systemic delivery of siRNA. Adv Drug Deliv Rev 2009;61:721-31. [PMID: 19328215 DOI: 10.1016/j.addr.2009.03.003] [Cited by in Crossref: 366] [Cited by in F6Publishing: 383] [Article Influence: 26.1] [Reference Citation Analysis]
|
| 85 |
Li M, Marin-Muller C, Bharadwaj U, Chow KH, Yao Q, Chen C. MicroRNAs: control and loss of control in human physiology and disease. World J Surg 2009;33:667-84. [PMID: 19030926 DOI: 10.1007/s00268-008-9836-x] [Cited by in Crossref: 144] [Cited by in F6Publishing: 126] [Article Influence: 10.3] [Reference Citation Analysis]
|
| 86 |
Podesta JE, Al-Jamal KT, Herrero MA, Tian B, Ali-Boucetta H, Hegde V, Bianco A, Prato M, Kostarelos K. Antitumor activity and prolonged survival by carbon-nanotube-mediated therapeutic siRNA silencing in a human lung xenograft model. Small 2009;5:1176-85. [PMID: 19306454 DOI: 10.1002/smll.200801572] [Cited by in Crossref: 33] [Cited by in F6Publishing: 68] [Article Influence: 2.4] [Reference Citation Analysis]
|
| 87 |
Gondi CS, Rao JS. Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol. 2009;220:285-291. [PMID: 19391103 DOI: 10.1002/jcp.21790] [Cited by in Crossref: 47] [Cited by in F6Publishing: 55] [Article Influence: 3.4] [Reference Citation Analysis]
|
| 88 |
Löb S, Königsrainer A, Rammensee HG, Opelz G, Terness P. Inhibitors of indoleamine-2,3-dioxygenase for cancer therapy: can we see the wood for the trees? Nat Rev Cancer 2009;9:445-52. [PMID: 19461669 DOI: 10.1038/nrc2639] [Cited by in Crossref: 334] [Cited by in F6Publishing: 341] [Article Influence: 23.9] [Reference Citation Analysis]
|
| 89 |
Sun HX, He HW, Zhang SH, Liu TG, Ren KH, He QY, Shao RG. Suppression of N-Ras by shRNA-expressing plasmid increases sensitivity of HepG2 cells to vincristine-induced growth inhibition. Cancer Gene Ther 2009;16:693-702. [PMID: 19247395 DOI: 10.1038/cgt.2009.14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 90 |
Chen Y, Huang L. Tumor-targeted delivery of siRNA by non-viral vector: safe and effective cancer therapy. Expert Opin Drug Deliv 2008;5:1301-11. [PMID: 19040393 DOI: 10.1517/17425240802568505] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 91 |
Wan J, Sazani P, Kole R. Modification of HER2 pre-mRNA alternative splicing and its effects on breast cancer cells. Int J Cancer 2009;124:772-7. [PMID: 19035464 DOI: 10.1002/ijc.24052] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
|
| 92 |
Matsuzaki S, Azuar AS, Mage G, Canis M. Impact of the surgical peritoneal environment on pre-implanted tumors on a molecular level: a syngeneic mouse model. J Surg Res 2010;162:79-87. [PMID: 19524269 DOI: 10.1016/j.jss.2008.12.026] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 93 |
Buchsbaum DJ, Miller CR, Mcnally LR, Kaliberov SA. Cancer gene therapy. Principles of Cancer Biotherapy 2009. [DOI: 10.1007/978-90-481-2289-9_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 94 |
Zou X, Qiao H, Jiang X, Dong X, Jiang H, Sun X. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J Biomed Sci 2009;16:33. [PMID: 19292890 DOI: 10.1186/1423-0127-16-33] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 95 |
Zou X, Qiao H, Jiang X, Dong X, Jiang H, Sun X. Downregulation of developmentally regulated endothelial cell locus-1 inhibits the growth of colon cancer. J Biomed Sci. [DOI: 10.1007/s11373-008-9284-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
